Text Size

Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

This study has been terminated.
Sponsor:
Information provided by:
Chiron Corporation
ClinicalTrials.gov Identifier:
NCT00051688
First received: January 15, 2003
Last updated: July 10, 2006
Last verified: July 2006
History of Changes
  Purpose

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.


Condition Intervention Phase
Colorectal Neoplasms
 Drug: tezacitabine
Drug: oxaliplatin
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Drug Information available for: Oxaliplatin
U.S. FDA Resources

Further study details as provided by Chiron Corporation:

Study Start Date: June 2003
Estimated Study Completion Date: August 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy.
  • Patients must have at least one measurable tumor.
  • Patients may not have received prior treatment with oxaliplatin.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00051688

Locations
United States, Arizona
ACRC/Arizona Clinical Research Center
Tucson, Arizona, United States, 85712
United States, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Comprehensive Cancer Centers of the Desert
Palm Springs, California, United States, 92262
Cancer Institute Medical Group
Santa Monica, California, United States, 90404
United States, District of Columbia
Georgetown University Medical Center, Lombardi Cancer Center
Washington, District of Columbia, United States, 20007
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612-9497
United States, Illinois
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 60611
United States, Missouri
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States, 64111
Sponsors and Collaborators
Chiron Corporation
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00051688     History of Changes
Other Study ID Numbers: TEZ101
Study First Received: January 15, 2003
Last Updated: July 10, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
 Rectal Diseases
Oxaliplatin
2'-deoxy-2'-(fluoromethylene)cytidine
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Radiation-Sensitizing Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 22, 2013